skip to Main Content

Diabetes Drugmakers Must Face Claims Over Pancreatic Cancer Risk

Newsfeed image, light gray text on dark gray background
A California appeals court reversed a grant of summary judgment to a group of drugmakers accused of failing to warn that their type 2 diabetes medications increased users’ risk of developing pancreatic cancer.

The claims against Merck Sharp & Dohme Corp, the maker of Janumet and Januvia; Novo Nordisk Inc, the manufacturer of Victoza; and AstraZeneca’s Amylin Pharmaceuticals, which produces Byetta, are not preempted by federal law, a unanimous three-judge panel of the California Court of Appeals in Los Angeles found on Tuesday. Read more . . .

Back To Top